Paul Hastings LLP has advised Current. Current has completed an $80 million Series E equity financing at a $1.5 billion valuation, with the round led by...
Current Raises $80 Million in Series E Funding Led by Springcoast Partners
Semperis Acquires MightyID to Expand Cyber Resilience Capabilities
Paul Hastings LLP has advised Semperis on its acquisition of MightyID. Semperis, a company focused on identity-driven cyber resilience and crisis management, has completed the acquisition...
Semperis’$125 Million Growth Financing
Paul Hastings LLP advised Semperis on the deal. Semperis, a pioneer in identity-driven cyber resilience, announced it secured $125 Million in growth financing from J. P....
Orchestra BioMed’s $110 Million Series D Financing
Paul Hastings LLP advised Orchestra BioMed on the deal. Orchestra BioMed, a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, announced the closing of a $110...
Orchestra BioMed’s Collaboration with Medtronic
Paul Hastings LLP advised Orchestra BioMed on the deal. Orchestra BioMed announced a strategic collaboration with Medtronic to develop Orchestra BioMed’s BackBeat Cardiac Neuromodulation Therapy™ (CNT™) as...
Orchestra BioMed’s Merger with Health Sciences Acquisitions Corporation 2
Paul Hastings LLP advised Orchestra BioMed on the deal. Loeb & Loeb LLP served as legal counsel for HSAC2. Latham & Watkins LLP represented the capital...